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Introduction
The ErbB2 oncogene (also known as HER2) belongs to the epidermal growth factor-receptor family and its over-expression and activation have been detected in a large subset of mammary cancers (Hynes and Lane, 2005) . Amplification or over-expression of the ErbB2 gene has been detected in many cancers, including human breast, lung and gastric cancers and is associated with increased tumor grade and shorter overall survival rates (Allgayer et al., 2000; Sharma and Settleman, 2009; Slamon et al., 1989) . ErbB2 activation is associated with an increase of its tyrosine phosphorylation and results in the phosphorylation of a host of downstream molecules, which in turn activate a variety of signalling cascades, including phosphatidylinositol-3 kinase (PI3K)/Akt, Src kinase, phospholipase C gamma and the RAS/mitogen activated protein kinase cascade (Baselga and Swain, 2009; Hynes and Lane, 2005; Hynes and MacDonald, 2009; Neve et al., 2002; Yarden and Sliwkowski, 2001 ). p130Cas was originally identified as a tyrosine phosphorylated protein upon transformation by vand v-Crk oncogenes and for its ability to associate with Crk (Matsuda et al., 1990; Reynolds et al., 1989) . p130Cas is a multifunctional adaptor protein required for embryonic development (Honda et al., 1998) and is characterized by structural motifs that enable interactions with a variety of signaling molecules. These multi-protein complexes sense and integrate signalling originating from several receptor systems (Bouton et al., 2001; Defilippi et al., 2006; O'Neill et al., 2000) . p130Cas functions as a molecular scaffold within focal adhesion complexes, and is readily phosphorylated by focal adhesion kinase (FAK) and c-Src (Mitra and Schlaepfer, 2006) . For its inclusion in focal adhesion complexes, p130Cas has also been proposed to play a critical role in mediating cell migration and invasion. Indeed, fibroblasts derived from p130Cas-deficient embryos exhibit drastically altered cytoskeletal architectures (Honda et al., 1998) and after transformation with c-Src become significantly more invasive when engineered to simultaneously over-express p130Cas (Brabeck 2004) . In addition, p130Cas association with Crk constitutes a molecular switch for cell motility by recruiting DOCK180 to integrin-containing adhesion complexes (Klemke et al.,
Material and Methods

Antibodies and reagents
Mouse monoclonal antibodies to p130Cas and beta-1 integrin and rabbit polyclonal antibodies to fibronectin were produced at the MBC, University of Torino. Phospho Src (Y416), phospho Erk1/2 (T202/T204), phospho Akt (S473), phospho S6Rp (S235/236), S6Rp, Erk1/2 MAPK, Akt, phospho p70S6K T389 and T421/S424, p70S6K antibodies were obtained from Cell Signaling (Beverly, MA), Rac1 antibody was from Millipore (Billerica, MA, USA). c-Src antibody was from Santa Cruz (Palo Alto, CA, USA). Rac inhibitor (NSC23766) was from Calbiochem (Merck KGaA, Darmstadt, Germany), MAPKK inhibitor (PD98059), Src inhibitor (SU6656) and PI3K inhibitor (LY294002) from Sigma (St. Louis, MO, USA), Rapamycin was from Cell signalling. Matrigel and collagen I were purchased from BD Trasduction Laboratories (Franklin Lakes, NY). Secondary antibodies conjugated with peroxidase were purchased from GE Healthcare. Alexa Fluor 633 phalloidin and Alexa Fluor Dye secondary antibodies were from Invitrogen (Carlsbad, CA, USA).
Cell cultures
MCF10A.B2 engineered cells were kindly provided by Dr. Muthuswamy (Cold Spring Harbor Laboratory), (Muthuswamy et al., 2001) . MCF10A.B2 cells were maintained in DMEM/F12 (Gibco, BRL) supplemented with 5% horse serum, 20 ng/ml EGF, 10 g/ml insulin, 1 ng/ml cholera toxin, 100 g/ml hydrocortisone, 50 U/ml penicillin and 50 g/ml streptomycin. To generate 10A.B2Mock and 10A.B2Cas cells, we transduced MCF10A.B2 with pBabe retroviral empty vector or carrying p130Cas cDNA fused with GFP.
Three-dimensional morphogenetic assay
3D
morphogenetic assays were conducted as previously described in http://muthuswamylab.cshl.edu/ml_protocols.html and in (Debnath et al., 2003; Seton-Rogers et al., 2004) . Phase images were collected by using Zeiss microscopy at 4X magnitude.
Immunobloting analysis from 3D cultures
3D acini were released from Matrigel:Collagen using BD cell recovery solution (BD Biosciences).
Protein extracts were obtained by lysing acini with RIPA buffer (50mM Tris-HCl pH 7.4, 150mM
NaCl; 1% Triton X-100, and protease inhibitors 
Rac pull-down assay
Rac1 pull-down assay was performed as described in (Di Stefano et al., 2007) . Briefly, glutathionecoupled Sepharose 4B beads bound to recombinant GST-PAK CRIB domain fusion proteins were incubated with cell extracts at 4°C for 45 min, eluted in Laemmli buffer and analysed for the presence of Rac1 by Western blot.
In silico analysis
The NKI dataset for early stage breast cancer containing 295 breast cancer specimens, analysed on a 25,000 spot oligonucleotide array as described previously, was used (van de Vijver et al., 2002) .
Only the 102 patients positive for ErbB2 expression (expression above the mean) were considered.
The difference in ErbB2 expression between patients with high levels of p130Cas and with low levels of p130Cas (with respect to the mean expression level across the samples) was determined with a two-sided Mann-Whitney U test.
Distant metastasis-free survival times was defined as the time to the first event. Overall survival times were based on death from any cause. Patients were censored at last follow up. Kaplan-Meier survival curves were compared using a log-rank test (R survival package).
Results
In human breast tumours p130Cas and ErbB2 co-expression correlates with metastasis and poor prognosis
Our previous data indicate that p130Cas is involved in ErbB2 tumorigenesis (Cabodi et al., 2006) and is required for lung colonisation of ErbB2-transformed cells (Cabodi et al., 2010) . The clinical relevance of these findings is supported by the in silico analysis that we performed using publicly available microarray data from the Netherlands Cancer Institute of 295 early stage breast cancer biopsies (van de Vijver et al., 2002) . On this set of data we evaluated the expression of p130Cas in patients that were positive for ErbB2 (102 out of 295). Interestingly, as shown in the boxplot in Figure 1A , the expression of ErbB2 is significantly higher in patients with high levels of p130Cas have a shorter overall survival (P = 0.012, Figure 1B ) and, interestingly, a higher risk of developing distant site metastasis (P = 0.0445, Figure 1C ) compared to patients with low levels of p130Cas.
Thus, ErbB2 and p130Cas co-expression in this cohort of breast cancer patients significantly correlates with metastasis and poor prognosis, supporting the relevance of p130Cas and ErbB2 cooperation in promoting breast cancer progression. Increasing evidences indicate that both the PI3K/Akt and the Erk1/2 MAPK signalling can activate mTOR/p70S6K pathway (Klos et al., 2006; Lehman and Gomez-Cambronero, 2002; Sekulic et al., 2000) . Deregulation of the mTOR/p70S6K pathway may play an important role in cancer progression as well as in many other diseases (Hay and Sonenberg, 2004; Holland et al., 2004) .
Activation of p70S6K is a multistep process starting with the priming phosphorylation on residues T421 and S424 within the auto-inhibitory domain by kinases such as Erk1/2 MAPKs, followed by phosphorylation of T389 by mTOR that is critical for p70S6K activation (Pearson et al., 1995; Saitoh et al., 2002; Thomas, 1993 Consequently, to analyze the effect of p130Cas over-expression on ErbB2-dependent activation of the p70S6K pathway, 3D cultures of 10A.B2Mock and 10A.B2Cas were treated or untreated with AP1510. p70S6K activity was assessed in cell extracts using phosphospecific antibodies directed against p70S6K and the ribosomal subunit protein S6 (S6Rp), a known downstream target of p70S6K. Our results indicate that upon ErbB2 activation, p70S6K and its substrate S6Rp are more phosphorylated in 10A.B2Cas cells than in 10A.B2Mock cells ( Figure 3A) . Moreover, to evaluate whether the enhanced activation of p70S6K is relevant for ErbB2-dependent invasiveness of 10A.B2Cas acini, we used the pharmacological inhibitor rapamycin, which specifically blocks p70S6K by acting on its upstream activator mTOR. Treatment with 20 nanomolar rapamycin was indeed sufficient to strongly reduce the phosphorylation of p70S6K on T389 and of its substrate S6Rp ( Figure 3B ) and to severely impair the formation of invasive protrusions in AP1510-treated 10A.B2Cas multiacinar structures ( Figure 3C ), indicating that p70S6K plays a critical role in driving ErbB2-induced invasion in p130Cas over-expressing cells.
p130Cas over-expression enhances ErbB2-dependent mTOR/p70S6K activation via Erk1/2
MAPK.
To understand the signalling pathways coordinated by p130Cas and ErbB2 resulting in activation of mTOR/p70S6K and leading to invasion, we examined the contribution of PI3K/Akt and Erk1/2 MAPK on p70S6K activation by using specific inhibitors. Specifically, to explore the effect of PI3K/Akt on p70S6K activity, 10A.B2Cas cells, left unstimulated or stimulated with AP1510, were treated with 10 micromolar LY294002. As shown in Figure 4 , the pharmacological inhibition of PI3K results in the reduced phosphorylation of Akt on S473 and does not affect Erk1/2 phosphorylation. In parallel, p70S6K1 and its target S6Rp are still phosphorylated on T389 and S235/236, respectively, indicating that PI3K inhibition does not significantly alter p70S6K1
activation. Instead, the treatment with 25 micromolar of the MEK inhibitor PD98059 reduces Erk1/2 MAPK phosphorylation and impairs p70S6K and S6Rp phosphorylation, without affecting Akt phosphorylation. Taken together these data indicate that in response to ErbB2 activation, p130Cas over-expression enhances the mTOR/p70S6K pathway via Erk1/2 MAPK activation in a PI3K/Akt independent manner.
p130Cas-dependent invasion of ErB2 transformed cells requires Rac1 activation via PI3K.
It is known that p130Cas promotes actin remodelling by a conserved pathway involving the activation of the small GTPase Rac1 Tikhmyanova et al., 2009) . Notably, in this work, Rac1 activity was measured in 3D culture conditions by pull down assay from extracts of AP1510-stimulated 10A.B2Mock or 10A.B2Cas acini. The concomitant over-expression of p130Cas and ErbB2 activation lead to enhanced Rac1 activity compared to 10A.B2Mock ( Figure   5A ). Interestingly, inhibition of PI3K with LY294002 prevents the increase in Rac1 activity in response to AP1510 in 10A.B2Cas acini, indicating that p130Cas over-expression coupled to ErbB2 activation enhances Rac1 activity through the PI3K/Akt pathway ( Figure 5A ).
Finally, we examined the involvement of Rac1 in 3D ErbB2-mediated invasion of 10A.B2Cas acini by using 80 micromolar NSC23766, a specific Rac1 inhibitor. As shown in Figure 5B , the inhibition of Rac1 in AP1510-stimulated 10A.B2Cas abolished the formation of invasive protrusions into the surrounding matrix. Importantly, the inhibition of Rac1 does not affect upstream pathways as demonstrated by the phosphorylation of Akt, Erk1/2 or S6Rp ( Figure 5C ). In conclusion, our results demonstrate that in ErbB2 transformed 10A.B2Cas cells, the increased activity of Rac1 is dependent on PI3K activity and is required for the invasive behaviour of these cells.
Invasive p130Cas over-expressing 10A.B2 cells with activated ErbB2 form 3D matrix
adhesions. 
The interactions of cells with extracellular matrix (ECM) mediated by integrin receptors
Discussion
In the present work we dissect the signalling pathways through which p130Cas confers invasive properties to ErbB-2 activated MCF10A.B2 cells by using a 3D model rather than the traditional monolayer culture. We show that the invasive behaviour of p130Cas over-expressing acini upon ErbB2 activation relies on the strengthening of Erk1/2 MAPK and PI3K/Akt activation.
Interestingly, the treatment with pharmacological inhibitors indicates that these signalling pathways are both required in order to promote invasion of acinar structures. Moreover, we demonstrate that Erk1/2 MAPK and PI3K/Akt signalling confers invasive properties through activation of mTOR/ p70S6K and Rac1, as two distinct downstream effectors (Figure 7) . Notably, invading epithelial cells over-expressing p130Cas and with activated ErbB2 are characterized by 3D matrix adhesions that have a distinct architecture compared to 2D adhesions.
MCF10A.B2 cells, that stably express a chimeric form of ErbB2, give rise to 3D multiacinar structures upon ErbB2 activation with a synthetic ligand. These multiacinar acini do not progress into an invasive phenotype (Muthuswamy et al., 2001) . We showed that ErbB2-activated MCF10A.B2 cells acquire the ability to invade in 3D as the result of p130Cas over-expression, indicating that high levels of p130Cas are sufficient to drive invasiveness of ErbB2-positive mammary epithelial cells (Cabodi et al., 2010) . However, the molecular events responsible for p130Cas-dependent invasiveness of ErbB2 transformed cells are not fully defined.
In monolayer cell cultures, the activation of ErbB2 receptors has been reported to induce signalling events, including sustained activation of c-Src, Erk1/2 MAPK and PI3K/Akt pathways that have been mainly related to cancer cell growth and survival (Graus-Porta et al., 1995; Hu et al., 1992; Karunagaran et al., 1996; Marcotte et al., 2009) In this work, we identify the mTOR/p70S6K pathway, as a novel effector signalling of p130Cas-dependent invasion of ErbB2 transformed cells. Although it has been reported that both Erk1/2 MAPK and PI3K/Akt signalling pathways can lead to mTOR/p70S6K activation (Inoki et al., 2002; Kelleher et al., 2004; Lehman and Gomez-Cambronero, 2002; Sekulic et al., 2000) , our results
show that in a three-dimensional model the preferential pathway that induce mTOR/p70S6K activation depends on ErbB2/p130Cas/Erk1/2 MAPK cascade. This is supported by the fact that the treatment with MEK inhibitor markedly reduces p70S6K activation. In contrast, PI3K inhibition does not significantly affect Erk1/2 MAPK phosphorylation or p70S6K activation. Thus, p130Cas
over-expression might preferentially conveys ErbB2 signalling to p70S6K through enhanced Erk1/2 MAPK activity that overcomes the PI3K/Akt pathway in the regulation of mTOR/p70S6K cascade.
The fact that ErbB2 dependent activation of Akt in presence of over-expression of p130Cas is not involved in mTOR/p70S6K phosphorylation requires further investigation. Therefore, p130Cas
over-expression further enhances the ErbB2-dependent activation of Erk1/2 MAPK thus promoting phosphorylation and activation of its downstream target mTOR/p70s6K that is required for cell invasion. Indeed, treatment with rapamycin, a selective inhibitor of mTOR, is sufficient to inhibit cell invasion.
Notably, it has been assessed that in human breast cancer, ErbB2 over-expression significantly correlates with p70S6K phosphorylation and this correlation was reported to be crucial for inducing angiogenesis and metastasis formation, underlining the clinical relevance of the activation of the mTOR/p70S6K in ErbB2 positive breast carcinoma (Klos et al., 2006) .
In the metastatic process of cancer invasion, the degradation of the extracellular matrix is one of the most critical step (Deryugina and Quigley, 2006; Yu et al., 1997) . It has been reported that p70S6K
promotes cell migration and invasion of an ovarian cancer cell line over-expressing ErbB2 by upregulating transcription of Matrix Metalloproteinase-9 (MMP-9) (Zhou and Wong, 2006) .
Interestingly, MMP-9 activity is higher upon concomitant activation of ErbB2 and p130Cas overexpression in mammary epithelial cells grown as a monolayer culture (Cabodi et al., 2010) . It is likely that one of the final targets of the mTOR/p70S6K signalling cascade may be the induction of MMP-9 that enables p130Cas over-expressing acini to invade into the extracellular matrix upon ErbB2 activation (Figure 7) . Consistently, treatment with MMP-9 inhibitor, abrogates the formation of invasive protrusions in ErbB2 transformed acinar structures over-expressing p130Cas
(data not shown).
In addition, our results identify Rac1 as a downstream effector of the PI3K/Akt pathway that is required for invasion of mammary epithelial acini. We have demonstrated that the concomitant over-expression of p130Cas and activation of ErbB2 drive Rac1 activity in 3D conditions.
Interestingly, treatment with the PI3K inhibitor was sufficient to decrease Rac1 activation to control levels. Since we have shown that the PI3K inhibition does not affect the Erk1/2 MAPK pathway, it is likely that Erk1/2 MAPK are not involved in the enhanced activity of Rac1. In addition, we show that Rac1 is required for invasion, as demonstrated by the absence of invasive protrusions in response of Rac1 inhibitor. It is well documented that p130Cas plays a crucial role in regulating actin cytoskeleton remodelling by controlling Rac1 activity Grimsley et al., 2004; Hsia et al., 2003) . In addition, it has been reported that p130Cas can associate with the p85 subunit of PI3K in transformed cells (Li et al., 2000; Riggins et al., 2003) . Therefore, we can speculate that in ErbB2 transformed mammary epithelial cells, high levels of p130Cas may facilitate the recruitment and activation of PI3K by ErbB2, that subsequently promote Rac1 activation, actin cytoskeleton re-organization, cell motility and invasion (Figure 7) . Although it is known that the PI3K/Akt/Vav2 pathway can lead to the activation of Rac1 (King et al., 2000; Papakonstanti and Stournaras, 2002; Welch et al., 2003) , the mechanisms that drive PI3K-dependent Rac1 activation in p130Cas over-expressing acini upon ErbB2 activation remain to be elucidated.
Overall, it is important to highlight that neither the Erk1/2 MAPK/p70S6K nor the PI3K/Akt/Rac1 pathway is sufficient by itself to elicit cell invasion. Indeed, the inhibition of either one pathway blocks the invasive process without affecting the other one. Therefore, the invasive process may be the result of the activation of Erk1/2 MAPK/p70S6K and PI3K/Akt/Rac1 pathways that target not overlapping effectors involved in distinct functional events. Alternatively, these two signalling pathways may converge on the same downstream effector, whose activation occurs only in presence of the additive effects of both signalling pathways.
Importantly, the results of the in silico analysis that we performed by using publicly available microarray data from the Netherlands Cancer Institute, (van de Vijver et al., 2002) indicate that patients with ErbB2 positive breast cancers and expressing high levels of p130Cas have a higher risk of developing metastasis and a shorter overall survival compared to patients with ErbB2
positive breast cancers for but with lower levels of p130Cas expression. These data suggest that expression of p130Cas might serve as indicator of ErbB2 breast cancer progression.
In summary, our data emphasize the crucial role of the concomitant over-expression of p130Cas
and ErbB2 activation in promoting cell invasion. Our data suggest that high levels of p130Cas expression function as a molecular switch that by amplifying signals from active ErbB2 and intracellular cues promotes the progression from the proliferative to the invasive behaviour, pointing out a possible role for p130Cas as a predictive marker for ErbB2 breast cancer progression.
Most importantly, as p130Cas controls several ErbB2 activated signalling pathways, its targeting is likely to be effective for the treatment of ErbB2 over-expressing and invasive breast tumours. 
